Fundz

Who to call at Georgiamune, and when

Fundz watches for the moments Georgiamune starts buying, and tells you who to reach.

  • An alert the day Georgiamune raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Georgiamune, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Georgiamune. With Fundz connected, it knows.

See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Menarini and Georgiamune Enter $1.1 Billion License Agreement for Cancer Immunotherapy GIM-621.

Oct 25, 2026

Contract Type

agreement

GaithersburgBiotechnologyHealth CareMedicalTherapeutics

Description

Menarini and Georgiamune have announced a worldwide license and collaboration agreement for GIM-621, a groundbreaking cancer immunotherapy. Georgiamune will receive $45 million in upfront payments, with the total deal potentially reaching $1.1 billion including additional royalties.

Company Information

Company

Georgiamune

Location

Gaithersburg, Maryland, United States

About

Georgiamune Inc. is a clinical-stage science and discovery biotechnology company focused on reprogramming immune signaling pathways to redirect the immune system to fight diseases. Georgiamune has designed unique approaches to re-establish immune balance, and its scientific discoveries have led to pioneering immunotherapies targeting high unmet needs. The company's lead program, GIM-122, is a first-in-class, dual-functioning monoclonal antibody. GIM-122 is designed to overcome immune therapy resistance in cancer patients. In addition to its lead program, the company is advancing a pipeline of first-in-class therapies for cancer and autoimmune diseases.

Related People

Mark
Likely contact at this company
••••••••@••••••••

See Mark's verified email →

Create an account to reveal verified emails
Predictive Intelligence
Strategic

ML-powered predictions for Georgiamune's next move

Learn about Strategic plan

Georgiamune signed a new agreement. Fundz surfaces partnerships and contracts as they are announced.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.